MX2025001995A - Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo - Google Patents
Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismoInfo
- Publication number
- MX2025001995A MX2025001995A MX2025001995A MX2025001995A MX2025001995A MX 2025001995 A MX2025001995 A MX 2025001995A MX 2025001995 A MX2025001995 A MX 2025001995A MX 2025001995 A MX2025001995 A MX 2025001995A MX 2025001995 A MX2025001995 A MX 2025001995A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compound
- preparing same
- pharmaceutical use
- preparing
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto heterocíclico, un método para prepararlo y su uso farmacéutico. Específicamente, la presente invención se refiere a un compuesto heterocíclico representado por la fórmula general (I), un método para prepararlo, una composición farmacéutica que lo comprende y su uso como agente terapéutico, particularmente, su uso como inhibidor de Nav y su uso en la preparación de un medicamento para tratar y/o aliviar el dolor y una enfermedad relacionada con el dolor. Los grupos en la fórmula general (I) son como se definen en la descripción. (ver Fórmula).
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211019508 | 2022-08-24 | ||
| CN202211211152 | 2022-09-30 | ||
| CN202211570844 | 2022-12-08 | ||
| CN202310117126 | 2023-02-15 | ||
| CN202310176022 | 2023-02-28 | ||
| CN202310272811 | 2023-03-20 | ||
| CN202310479094 | 2023-04-28 | ||
| CN202310550829 | 2023-05-16 | ||
| CN202310605968 | 2023-05-26 | ||
| CN202310675380 | 2023-06-08 | ||
| CN202310740371 | 2023-06-21 | ||
| PCT/CN2023/114740 WO2024041613A1 (zh) | 2022-08-24 | 2023-08-24 | 杂环类化合物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001995A true MX2025001995A (es) | 2025-04-02 |
Family
ID=90012617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001995A MX2025001995A (es) | 2022-08-24 | 2025-02-18 | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260055088A1 (es) |
| EP (1) | EP4578852A4 (es) |
| JP (1) | JP2025529841A (es) |
| KR (1) | KR20250052383A (es) |
| CN (1) | CN119585260A (es) |
| AU (1) | AU2023328112A1 (es) |
| MX (1) | MX2025001995A (es) |
| TW (1) | TW202409017A (es) |
| WO (1) | WO2024041613A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024188367A1 (zh) * | 2023-03-10 | 2024-09-19 | 西藏海思科制药有限公司 | 一种四氢呋喃衍生物及其在医药上的应用 |
| CN118812519A (zh) * | 2023-04-19 | 2024-10-22 | 武汉人福创新药物研发中心有限公司 | 取代的四氢呋喃作为Nav1.8抑制剂 |
| KR20260118418A (ko) | 2023-10-23 | 2026-07-30 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| AR134204A1 (es) * | 2023-11-01 | 2025-12-10 | Insilico Medicine Ip Ltd | Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos |
| TW202535352A (zh) * | 2023-11-02 | 2025-09-16 | 大陸商陽光安津(南京)生物醫藥科技有限公司 | 化合物、組合物及其方法 |
| EP4775574A1 (en) * | 2023-11-21 | 2026-07-15 | Wuhan Xirui Pharmaceutical Technology Co., Ltd | Furan ring-containing compound, pharmaceutical composition thereof, and use thereof |
| CN120192286A (zh) * | 2023-12-21 | 2025-06-24 | 武汉熙瑞医药科技有限公司 | 一种含苯环的多环化合物、其药物组合物及其应用 |
| CN120192305A (zh) * | 2023-12-21 | 2025-06-24 | 武汉熙瑞医药科技有限公司 | 一种含苯环的多环化合物、其药物组合物及其应用 |
| CN120040430B (zh) * | 2024-02-23 | 2026-06-05 | 山东盛迪医药有限公司 | 一种取代四氢呋喃衍生物的可药用盐、其结晶形式及用途 |
| CN120040429B (zh) * | 2024-02-23 | 2026-03-31 | 山东盛迪医药有限公司 | 一种取代四氢呋喃衍生物的结晶形式及其用途 |
| CN120058685B (zh) * | 2024-02-23 | 2026-06-09 | 山东盛迪医药有限公司 | 一种取代四氢呋喃化合物的结晶形式及其制备方法 |
| CN120058686B (zh) * | 2024-02-23 | 2026-06-09 | 山东盛迪医药有限公司 | 一种取代四氢呋喃化合物的可药用盐、其结晶形式及用途 |
| WO2025209562A1 (zh) * | 2024-04-03 | 2025-10-09 | 武汉人福创新药物研发中心有限公司 | 作为Nav1.8抑制剂的四氢呋喃吡啶酮类化合物 |
| WO2025218764A1 (zh) * | 2024-04-19 | 2025-10-23 | 广州市联瑞制药有限公司 | 作为电压门控钠通道抑制剂的化合物及其应用 |
| CN118388466A (zh) * | 2024-04-23 | 2024-07-26 | 安润医药科技(苏州)有限公司 | 作钠通道调节剂的酰胺衍生物及其用途 |
| WO2025252109A1 (zh) * | 2024-06-04 | 2025-12-11 | 成都苑东生物制药股份有限公司 | 一种取代四氢呋喃类衍生物、其制备方法及用途 |
| CN121085873A (zh) * | 2024-06-07 | 2025-12-09 | 济川药业集团有限公司 | 一种用作电压门控钠通道抑制剂的杂环类化合物及其药物组合物、药物制剂和应用 |
| TW202606663A (zh) | 2024-06-28 | 2026-02-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
| WO2026124645A1 (zh) * | 2024-12-13 | 2026-06-18 | 广州市联瑞制药有限公司 | 作为电压门控钠通道抑制剂的化合物及其应用 |
| WO2026145584A1 (zh) * | 2025-01-03 | 2026-07-09 | 江西科睿药业有限公司 | 一种杂环类化合物、其药物组合物、其中间体及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| AU2018300150A1 (en) * | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| GEAP202315648A (en) * | 2018-11-02 | 2023-07-25 | Merck Sharp & Dohme Llc | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020103817A1 (zh) | 2018-11-20 | 2020-05-28 | 南京圣和药业股份有限公司 | TGF-βR1抑制剂及其应用 |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| TW202214630A (zh) | 2020-09-12 | 2022-04-16 | 大陸商成都倍特藥業股份有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用 |
| WO2022256842A1 (en) * | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| US20240368135A1 (en) * | 2021-06-04 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CN117794918A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃类似物作为钠通道调节剂 |
| CA3221939A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
-
2023
- 2023-08-24 CN CN202380055347.3A patent/CN119585260A/zh active Pending
- 2023-08-24 EP EP23856701.0A patent/EP4578852A4/en active Pending
- 2023-08-24 TW TW112131922A patent/TW202409017A/zh unknown
- 2023-08-24 US US19/105,401 patent/US20260055088A1/en active Pending
- 2023-08-24 WO PCT/CN2023/114740 patent/WO2024041613A1/zh not_active Ceased
- 2023-08-24 AU AU2023328112A patent/AU2023328112A1/en active Pending
- 2023-08-24 KR KR1020257006465A patent/KR20250052383A/ko active Pending
- 2023-08-24 JP JP2025510376A patent/JP2025529841A/ja active Pending
-
2025
- 2025-02-18 MX MX2025001995A patent/MX2025001995A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024041613A1 (zh) | 2024-02-29 |
| EP4578852A1 (en) | 2025-07-02 |
| JP2025529841A (ja) | 2025-09-09 |
| CN119585260A (zh) | 2025-03-07 |
| US20260055088A1 (en) | 2026-02-26 |
| KR20250052383A (ko) | 2025-04-18 |
| TW202409017A (zh) | 2024-03-01 |
| EP4578852A4 (en) | 2025-12-17 |
| AU2023328112A1 (en) | 2025-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014378A (es) | N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio. | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| MX2024013020A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
| CR20240514A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| TW200806299A (en) | Treatment of pain | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| MX2011009709A (es) | Compuestos para el tratamiento de la inflamacion y del dolor. | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2024011705A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica | |
| MY143568A (en) | 11b-hsd1 inhibitors for the treatment of diabetes | |
| WO2009019708A3 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| MX2025009374A (es) | Compuesto que contiene trifluorometilsulfonilo | |
| EA200601249A1 (ru) | Пиперазины, пригодные для лечения боли | |
| MX2024015882A (es) | Derivados de 3-(sulfonil o sulfonimidoil)prop-2-en-1-il]-2-oxo-1,2-dihidropiridina-3-carboxamida | |
| MXPA05010020A (es) | Derivados de oxamida. |